Paul S.
- Country
- France
- Department
- Hématologie, oncologie et immunologie pédiatrique
Research Overview
- Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
- Safety and Efficacy of Asciminib, Blinatumomab, and Combination Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory BCR::ABL1+ or Ph-like ALL
- International Pediatric Study of Arsenic Trioxide and Tretinoin ± Gemtuzumab Ozogamicin for Acute Promyelocytic Leukemia in Children and Adolescents
Data & Insights
Has run more than one trial at 135 of 227 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML), particularly focusing on cases involving FLT3 gene mutations in children, adolescents, and young adults. Their expertise extends to managing relapsed and refractory cases of AML.
- FLT3-mutated AML therapy
- Pediatric leukemia treatment
- Targeted molecular therapies
Blood Disorders
A significant focus of the investigator's work involves treating rare bleeding disorders, specifically Glanzmann Thrombasthenia. Their expertise includes evaluating novel therapeutic approaches for managing bleeding complications in patients with platelet function disorders.
- Bleeding disorder management
- Platelet function disorders
- Prophylactic treatments
Pediatric Oncology
The investigator has particular expertise in treating acute lymphoblastic leukemia (ALL) in infants and young patients. Their work includes specialized focus on KMT2A-rearranged infant ALL and innovative treatment protocols for improving survival outcomes.
- Infant leukemia treatment
- ALL protocol development
- Immunotherapy applications
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.